down arrow

Thermo Fisher Scientific, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8835561023
USD
575.24
-5.13 (-0.88%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

560.32579.62

52 Week

385.46610.97
Valuation
Technical
Day's Volume

CASH

531.19 k

Shareholding (Mar 2025)

FII

29.46%

Held by 730 FIIs

DII

37.16%

Held by 73 DIIs

Promoter

0.07%

How big is Thermo Fisher Scientific, Inc.?

22-Jun-2025

As of Jun 18, Thermo Fisher Scientific, Inc. has a market capitalization of $164.77 billion, with net sales of $42.90 billion and a net profit of $6.52 billion over the latest four quarters.

Market Cap: As of Jun 18, Thermo Fisher Scientific, Inc. has a market capitalization of 164,766.10 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Thermo Fisher Scientific, Inc. reported net sales of 42,898.00 million and a net profit of 6,519.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 49,584.00 million and total assets of 97,321.00 million.

Read More

What does Thermo Fisher Scientific, Inc. do?

22-Jun-2025

Thermo Fisher Scientific, Inc. develops and sells products in the Pharmaceuticals & Biotechnology industry, with recent net sales of $10.36 billion and a market cap of $164.77 billion. Key metrics include a P/E ratio of 26.00 and a dividend yield of 0.38%.

Overview: <BR>Thermo Fisher Scientific, Inc. develops, manufactures, and sells a range of products in the Pharmaceuticals & Biotechnology industry, and it operates within the large-cap market segment.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 10,364 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1,511 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 164,766.10 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Dividend Yield: 0.38% <BR>Debt Equity: 0.57 <BR>Return on Equity: 13.42% <BR>Price to Book: 3.34<BR><BR>Contact Details: <BR>Address: 168 3rd Ave, WALTHAM MA: 02451-7551 <BR>Tel: ['1 781 6221000', '1 781 6221111'] <BR>Fax: 1 781 6221207 <BR>Website: https://www.thermofisher.com/

Read More

Who are in the management team of Thermo Fisher Scientific, Inc.?

22-Jun-2025

As of March 2022, the management team of Thermo Fisher Scientific, Inc. includes Marc Casper (Chairman, President, and CEO), Thomas Lynch (Lead Independent Director), R. Alexandra Keith, Nelson Chai, C. Martin Harris, and Tyler Jacks (all Independent Directors). They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Thermo Fisher Scientific, Inc. includes the following individuals:<BR><BR>- Mr. Marc Casper, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Mr. Thomas Lynch, who is the Lead Independent Director.<BR>- Ms. R. Alexandra Keith, who is a Director.<BR>- Mr. Nelson Chai, who is an Independent Director.<BR>- Dr. C. Martin Harris, who is also an Independent Director.<BR>- Dr. Tyler Jacks, who serves as an Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Thermo Fisher Scientific, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Thermo Fisher Scientific, Inc. is fairly valued with a P/E ratio of 26 and an EV to EBITDA of 18.39, having recently outperformed the S&P 500 over the past week but lagging behind in one-year returns.

As of 17 October 2025, the valuation grade for Thermo Fisher Scientific, Inc. moved from expensive to fair. Based on the current metrics, the company appears fairly valued. Key ratios include a P/E ratio of 26, an EV to EBITDA of 18.39, and a Price to Book Value of 3.44. In comparison to peers, Abbott Laboratories has a P/E of 18.36 and Medtronic Plc has an EV to EBITDA of 15.08, indicating that Thermo Fisher is positioned competitively within its industry.<BR><BR>In terms of recent performance, Thermo Fisher's stock returned 2.69% over the past week, outperforming the S&P 500's return of 1.70%. However, its one-year return of -10.07% lags behind the S&P 500's 14.08%, suggesting that while the stock is currently fairly valued, it has struggled to keep pace with broader market trends.

Read More

Is Thermo Fisher Scientific, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Thermo Fisher Scientific, Inc. shows a bullish technical trend with positive signals from MACD and Bollinger Bands, despite a bearish weekly RSI and underperformance over longer periods compared to the S&P 500.

As of 24 October 2025, the technical trend for Thermo Fisher Scientific, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, and the KST shows a bullish weekly signal but a bearish monthly signal. Dow Theory reflects a mildly bullish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 6.23% and 22.33%, respectively, compared to the S&P 500's 1.92% and 2.32%. However, over longer periods, the stock has underperformed the benchmark, particularly in the 3-year and 5-year returns. Overall, the current technical stance is bullish, with moderate strength driven by the positive signals from MACD and Bollinger Bands.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 11.00

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 10.48% and Operating profit at 11.37%

 
3

Flat results in Jun 25

4

With ROCE of 10.03%, it has a attractive valuation with a 2.55 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 205,941 Million (Large Cap)

stock-summary
P/E

26.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.31%

stock-summary
Debt Equity

0.57

stock-summary
Return on Equity

13.56%

stock-summary
Price to Book

4.08

Revenue and Profits:
Net Sales:
10,855 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,619 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.72%
0%
18.72%
6 Months
43.84%
0%
43.84%
1 Year
7.64%
0%
7.64%
2 Years
15.95%
0%
15.95%
3 Years
2.17%
0%
2.17%
4 Years
-9.57%
0%
-9.57%
5 Years
20.54%
0%
20.54%

Thermo Fisher Scientific, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Thermo Fisher Scientific, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Thermo Fisher Scientific, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, and the KST shows a bullish weekly signal but a bearish monthly signal. Dow Theory reflects a mildly bullish stance on both weekly and monthly time frames. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 6.23% and 22.33%, respectively, compared to the S&P 500's 1.92% and 2.32%. However, over longer periods, the stock has underperformed the benchmark, particularly in the 3-year and 5-year returns. Overall, the current technical stance is bullish, with moderate strength driven by the positive signal...

Read More

Is Thermo Fisher Scientific, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Thermo Fisher Scientific, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. However, the weekly RSI is bearish, indicating some short-term weakness. The KST shows a bullish stance weekly but bearish monthly, while Dow Theory remains mildly bullish in both time frames. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 6.23% and 22.33% respectively, but lags behind on a year-to-date and one-year basis. Overall, the current technical stance is bullish, with moderate strength driven by the positive trend in moving averages and Bollinger Bands....

Read More

Is Thermo Fisher Scientific, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Thermo Fisher Scientific, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, supporting the bullish stance. However, the weekly RSI is bearish, indicating some short-term weakness. The daily moving averages are bullish, reinforcing the positive outlook. The Dow Theory shows a mildly bullish stance on both weekly and monthly time frames. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 6.23% and 22.33% compared to 1.92% and 2.32% for the index, respectively. However, over longer periods, the stock has underperformed the S&P 500, particularly in the 3-year and 5-year returns. Overall, the current technical stance is bullish, with moderate strength driven by the moving averages and Bollinger Bands....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.48%
EBIT Growth (5y)
11.37%
EBIT to Interest (avg)
11.00
Debt to EBITDA (avg)
2.32
Net Debt to Equity (avg)
0.57
Sales to Capital Employed (avg)
0.53
Tax Ratio
6.68%
Dividend Payout Ratio
9.43%
Pledged Shares
0
Institutional Holding
93.65%
ROCE (avg)
13.03%
ROE (avg)
16.96%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
3.44
EV to EBIT
25.43
EV to EBITDA
18.39
EV to Capital Employed
2.55
EV to Sales
4.61
PEG Ratio
4.99
Dividend Yield
0.36%
ROCE (Latest)
10.03%
ROE (Latest)
13.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 265 Schemes (33.29%)

Foreign Institutions

Held by 730 Foreign Institutions (29.46%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.74% vs -9.05% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 7.15% vs -17.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,855.00",
          "val2": "10,364.00",
          "chgp": "4.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,633.00",
          "val2": "2,545.00",
          "chgp": "3.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "471.00",
          "val2": "303.00",
          "chgp": "55.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-43.00",
          "val2": "-45.00",
          "chgp": "4.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,619.00",
          "val2": "1,511.00",
          "chgp": "7.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "179.50%",
          "val2": "177.50%",
          "chgp": "0.20%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.05% vs -4.58% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.43% vs -14.44% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "42,879.00",
          "val2": "42,857.00",
          "chgp": "0.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10,770.00",
          "val2": "10,852.00",
          "chgp": "-0.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1,654.00",
          "val2": "1,491.00",
          "chgp": "10.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-73.00",
          "val2": "-496.00",
          "chgp": "85.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,338.00",
          "val2": "5,955.00",
          "chgp": "6.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "178.70%",
          "val2": "173.70%",
          "chgp": "0.50%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
10,855.00
10,364.00
4.74%
Operating Profit (PBDIT) excl Other Income
2,633.00
2,545.00
3.46%
Interest
471.00
303.00
55.45%
Exceptional Items
-43.00
-45.00
4.44%
Consolidate Net Profit
1,619.00
1,511.00
7.15%
Operating Profit Margin (Excl OI)
179.50%
177.50%
0.20%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.74% vs -9.05% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 7.15% vs -17.16% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
42,879.00
42,857.00
0.05%
Operating Profit (PBDIT) excl Other Income
10,770.00
10,852.00
-0.76%
Interest
1,654.00
1,491.00
10.93%
Exceptional Items
-73.00
-496.00
85.28%
Consolidate Net Profit
6,338.00
5,955.00
6.43%
Operating Profit Margin (Excl OI)
178.70%
173.70%
0.50%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.05% vs -4.58% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 6.43% vs -14.44% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Thermo Fisher Scientific, Inc. stock-summary
stock-summary
Thermo Fisher Scientific, Inc.
Pharmaceuticals & Biotechnology
Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.
Company Coordinates stock-summary
Company Details
168 3rd Ave , WALTHAM MA : 02451-7551
stock-summary
Tel: 1 781 62210001 781 6221111
stock-summary
https://www.thermofisher.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."